Cancers 2021, 13, 1810 S1 of S37

Supplementary Materials: Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2-Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2-Breast Cancer

Sven Roßwag, Cristina L. Cotarelo, Klaus Pantel, Sabine Riethdorf, Jonathan P. Sleeman, Marcus Schmidt and Sonja Thaler





Figure S1. CTCs were derived from a patient with bi-lateral metastatic breast cancer. The patient was originally diagnosed with an invasive ductal carcinoma and an invasive lobular carcinoma. Characteristics of the tumors are given in the Figure.

Cancers **2021**, 13, 1810 S2 of S37






Figure S2. (A) + (B) Knockdown of FOXM1 displays differences between CTC-ITB-01 and MCF7 cells. (B) Knockdown of FOXM1 in MCF7 cells causes less reduction of colonies as observed within CTC-ITB-01 and induction of senescence as monitored by typical morphological changes. (A) In CTC-ITB-01 cells, we observed less cells with senescence-like morphology and cell debris indicating that FOXM1 knockdown causes mainly induction of senescence within MCF7 and more cell death within CTC-ITB-01 cells. Bar 400 μ m.

Cancers 2021, 13, 1810 S3 of S37




Figure S3. (**A**) + (**B**) CTC-ITB-01 and MCF7 cells were grown on cell culture plates or cultured in suspension. 24 hours after seeding cells on tissue culture plates or taking cells in suspension CTC-ITB-01 and MCF7 cells were harvested and lysates were analysed by western blotting and probed by using the indicated antibodies.




Figure S4. CTC-ITB-01 cells were cultured in suspension in the absence or presence of 30 μ M carfilzomib. After five days carfilzomib treatment lead to induction of apoptotic cell death.

Cancers 2021, 13, 1810 S4 of S37




Figure S5. (**A**) + (**B**) CTC-ITB-01 and MCF7 cells were serum starved overnight, than treated with TNF α + JSH-23 or with TNF α alone, and subsequently fixed and stained with an NFkB p65 antibody 20 min after TNF α treatment. In the presence of JSH-23 a strong reduction of cells with p65+ nuclei in the CTC-ITB-01 cells and in the MCF7 cells was observed. (**C**) After establishing the NF-kB p65 staining in this way, we cultured CTC-ITB-01 and MCF7 cells with JSH-23 as described in Figure 6D in the manuscript. Afterwards we repeated the NF-kB p65 staining and quantified the percentage of cells with p65+ nuclei. Again, we observed strong reduction of cells with p65+ nuclei (**C**) CTC-ITB-01 left panel, MCF7 cells right panel.

Cancers 2021, 13, 1810 S5 of S37






Figure S6. (A) + (B) CTC-ITB-01 and MCF7 cells were cultured in the presence or absence of JSH-23. mRNA was harvested and FOXM1 transcripts were quantified by qPCR.

Cancers **2021**, 13, 1810 S6 of S37

Figure 1B











Cancers **2021**, 13, 1810 S7 of S37


Figure 1C






Cancers **2021**, 13, 1810 S8 of S37






Cancers **2021**, 13, 1810 S9 of S37




Cancers 2021, 13, 1810 S10 of S37






AZD9496 [1µM]

Cancers **2021**, 13, 1810 S11 of S37




Cancers 2021, 13, 1810 S12 of S37






Cancers **2021**, 13, 1810 S13 of S37




Cancers 2021, 13, 1810 S14 of S37




HER2 k.o.2

Cancers **2021**, 13, 1810 S15 of S37




Cancers 2021, 13, 1810 S16 of S37






Cancers **2021**, 13, 1810 S17 of S37



Cancers 2021, 13, 1810 S18 of S37






Cancers **2021**, 13, 1810 S19 of S37




Cancers 2021, 13, 1810 S20 of S37






Cancers **2021**, *13*, 1810 S21 of S37




Cancers **2021**, 13, 1810 S22 of S37






Cancers **2021**, *13*, 1810 S23 of S37




Cancers 2021, 13, 1810 S24 of S37






Cancers 2021, 13, 1810 S25 of S37




Cancers 2021, 13, 1810 S26 of S37






Cancers **2021**, *13*, 1810 S27 of S37




Cancers 2021, 13, 1810 S28 of S37






Cancers 2021, 13, 1810 S29 of S37




Cancers 2021, 13, 1810 S30 of S37

Figure 5A




Cancers **2021**, *13*, 1810 S31 of S37




Cancers 2021, 13, 1810 S32 of S37





Cancers **2021**, 13, 1810 S33 of S37




Cancers 2021, 13, 1810 S34 of S37

Figure 6D



Cancers **2021**, *13*, 1810 S35 of S37



Cancers 2021, 13, 1810 S36 of S37

CTC-ITB-01













100 : 112



adherent





Cancers 2021, 13, 1810 S37 of S37




Figure S7. Original Uncropped Western Blot Images.